@docbmt

Haematologist @KingsCollegeNHS @myeloidkings #StemcellTransplantation #GVHD #MedicalMycology #loveToNetwork #BloodCancerResearch

 London, England
drvarunmehrahaematology.co.uk
Joined September 2012
  • Tweets330
  • Following337
  • Followers453
23Media
Varun Mehra retweeted
NEJM
@NEJMSep 2
In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: nej.md/4zJr1wV Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML nej.md/4cgnBHO
Shown are Kaplan–Meier curves for event-free survival (Panel A) and overall survival (Panel B) in the azacitidine–venetoclax and induction chemotherapy groups.

ALT Shown are Kaplan–Meier curves for event-free survival (Panel A) and overall survival (Panel B) in the azacitidine–venetoclax and induction chemotherapy groups.

6
101
15
252
47,323
Varun Mehra retweeted
GvHD Hub
@gvhd_hubJun 13
CONGRESS | #EHA2026 | PRESENTATION Johannes Schetelig presents findings from a randomized non-inferiority trial evaluating PTCy-100 vs ATLG-30 as #GvHD prophylaxis in allo-HSCT recipients from unrelated donors (N = 640). In the ITT population, the 2-year OS was 68% with PTCy-100 vs 75% with ATLG-30 (HR, 1.341; test for non-inferiority, p = 0.85; test for superiority, p = 0.051). The 2-year GRFS was 48% with PTCy-100 vs 40% with ATLG-30 (HR, 0.85; p = 0.16). The 2-year cumulative incidences of relapse were 26% and 31% (HR, 0.86), respectively. The 2-year NRM was 13% with PTCy-100 vs 7% with ATLG-30 (HR, 1.86; p = 0.02). Overall, confirmatory testing demonstrated that non-inferior survival with a 5% margin for PTCy-100 compared with ATLG-30 could not be shown. Follow our live feed for more updates: loom.ly/1BscQNI Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedicalCongress @DKMS_SciMed
1
5
11
799
Varun Mehra retweeted
NEJM
@NEJMJun 3
Original Article: Obexelimab for the Treatment of IgG4-Related Disease (phase 3 INDIGO trial results) nej.md/4fKYQG4 Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease nej.md/4fLybcd #EULAR2026 | @eular_org
Graph showing estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. The y-axis represents the probability of no flare, ranging from 0 to 1, and the x-axis shows time in months. The blue line indicates obexelimab while gray line indicates placebo. Notable statistics detail patients at risk, number of patients with flares, and median times. The hazard ratio is 0.44 with a p-value of <0.001.

ALT Graph showing estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. The y-axis represents the probability of no flare, ranging from 0 to 1, and the x-axis shows time in months. The blue line indicates obexelimab while gray line indicates placebo. Notable statistics detail patients at risk, number of patients with flares, and median times. The hazard ratio is 0.44 with a p-value of <0.001.

The image displays two line graphs. The top graph shows CD20+ B-cell counts over time in weeks, comparing placebo and obexelimab treatments. The bottom graph presents serum IgG4 levels. Both graphs include patient numbers at different stages.

ALT The image displays two line graphs. The top graph shows CD20+ B-cell counts over time in weeks, comparing placebo and obexelimab treatments. The bottom graph presents serum IgG4 levels. Both graphs include patient numbers at different stages.

2
37
4
104
22,041
Looking for a new Professor of Haematology and Head of the Department of Haematology at King's College London, based in the Denmark Hill campus. Closing date: May 4. For more info: kcl.ac.uk/jobs/142085-profes… @KHPHaematology @KCLcancer_pharm @KCLredcell @kingsmedicine
1
4
359
Varun Mehra retweeted
Uriel Suárez
@UsuarezMDApr 1
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…

American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very...

Background. Aplastic anemia is a rare, life-threatening condition marked by pancytopenia and bone marrow hypocellularity. Despite therapeutic advances, cli

ashpublications.org
29
1
85
4,138
Varun Mehra retweeted
GvHD Hub
@gvhd_hubMar 23
CONGRESS | #EBMT26 | PRESENTATION Florent Malard reports final results from the phase III, multicenter, open-label ARES trial, evaluating MaaT013 as a third-line treatment option in patients with treatment-refractory GI-#aGvHD after systemic steroids and ruxolitinib (N = 66). ARES met its primary endpoint, with a Day 28 GI-ORR of 62%, exceeding the pre-established threshold of 22% (p < 0.0001). Most patients had Day 28 GI-CR (38%) or GI-VGPR (20%), with 5% experiencing GI-PR. The all-organ ORR at Day 28 was 64%, and GI-ORR was maintained in 47% at Day 56 and 44% at Month 3. With a median follow-up of 344.5 days, the median OS was not reached; OS was 54% at Month 12, and was higher among Day 28 responders vs non-responders (68% vs 28%). Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedNews #MedEd @TheEBMT @Florent_Malard @crsa_paris
6
11
815
Varun Mehra retweeted
GvHD Hub
@gvhd_hub7 Dec 2025
CONGRESS | #ASH25 | POSTER Everett Meyer presents data from a subgroup analysis of the phase III Precision-T trial of Orca-T versus tacrolimus + methotrexate (Tac/MTX) in patients with acute leukemia (N = 182). At 1 year, Orca-T demonstrated improved rates of chronic GvHD-free survival (78% vs 38%; p < 0.0001), OS (94% vs 83%; p = 0.045), GRFS (63% vs 31%; p < 0.0001), and NRM (13% vs 3.4%; p = 0.037) compared to Tac/MTX. Orca-T vs Tac/MTX showed improved clinical outcomes across patient subgroups with varied demographic and clinical features, including age, sex, donor type, and conditioning regimen. Follow our live feed for more updates: loom.ly/MbPzIiA Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHD #GvHDsm #MedicalCongress @StanfordMed
3
8
657
Varun Mehra retweeted
LARVOL
@Larvol13 Jun 2025
AML at @EHA_Hematology 2025: Inqovi, Ziftomenib, Bleximenib, and More. Key updates on ORR, CR/CRi rates, and tolerability. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #AML #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @AlkaliDr | @LeukDocJZ | @calliecoombsmd | @hemedoc | @AaronGoodman33 | @TalhaBadarMD | @SuyogCancer
11
1
21
1,789
Varun Mehra retweeted
NEJM
@NEJM14 Jun 2025
Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) nej.md/3Zpri7z #EHA2025 | @EHA_Hematology
A graph showing the primary end point, which was graft-versus-host disease (GVHD)–free, relapse-free survival.

ALT A graph showing the primary end point, which was graft-versus-host disease (GVHD)–free, relapse-free survival.

A graph showing relapse-free survival, which was assessed in a post hoc exploratory analysis.

ALT A graph showing relapse-free survival, which was assessed in a post hoc exploratory analysis.

A graph showing overall survival, which was a secondary end point.

ALT A graph showing overall survival, which was a secondary end point.

33
1
126
20,922
Varun Mehra retweeted
LARVOL
@Larvol10 Jun 2025
Menin inhibitor studies at @EHA_Hematology 2025 in acute leukemia, focusing on NPM1-mutated and KMT2A-rearranged subsets. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #Leukemia #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @TalhaBadarMD | @smbenlazar | @hemedoc | @LeukDocJZ | @Abdallah81MD | @SuyogCancer
20
2
51
6,935
a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. ow.ly/Y03x50W7qaE #transplantation

A cure for the kiss of death?

In this issue of Blood Advances, Lontos1 et al provide a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the

ashpublications.org
3
16
1,649
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) nature.com/articles/s41375-0…
88
1
187
20,451
Take home messages on cGvHD #EBMT25 @Mohty_EBMT Best Belumosudil response takes time! >6mo to achieve it in some cases Most important… Great Impact on QoL! Very well tolerated treatment Good safety profile Great responses in heavily pretreated patients @TheEBMT
9
40
2,013
Varun Mehra retweeted
DonalMcLornan@DrLornan30 Mar 2025
👉🏼@TheEBMT Prediction of outcomes post allo-HCT in Myelofibrosis via ML. Practical online tool to aid the transplant decision and discussion #MPNsm #EBMT25 hematology.org/newsroom/pres… @TheEBMT @MosqueraOrgeira @AnnaSureda5 @TheEBMT_Trainee
ASH
@ASH_hematology27 Mar 2025
Replying to @ASH_hematology @TheEBMT
This tool outperformed standard models in accuracy, identifying a subset of high-risk patients with a 40% chance of dying within a year after transplant—25% of patients with myelofibrosis. This data helps patients weigh disease-related risk factors when considering a transplant.
2
11
3
39
5,068
Fascinating results of the 1st published study of HMA/Ven vs. 7+3 for younger AML pts in @BloodJournal. We cannot continue to Tx AML as a 1-size fits all paradigm. Intensive chemo still optimal for favorable-risk. But HMA/Ven may be best in select subgroups even in younger pts 👇
Talha Badar@TalhaBadarMD27 Feb 2025
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML ashpublications.org/blood/ar… 👉 Venetoclax plus decitabine NOT INFERIOR to intensive chemo in young fit AML. 👉VEN+DEC was well tolerated. #lesum #AML
2
14
2
49
5,317
🔥Just published🔥 @TheLancetInfDis @CornelyOliver @RosanneSprute Global guideline for the diagnosis and management of candidiasis: an an initiative of the @eurconfmedmycol in cooperation with @ISHAM_Mycology & @ASMicrobiology thelancet.com/journals/lanin…
3
131
3
306
54,868
Varun Mehra retweeted
Leukaemia UK
@LeukUK25 Feb 2025
Fantastic news! Blinatumomab has been approved by NICE for wider use in B-cell acute lymphoblastic leukaemia (B-ALL), meaning more patients now have access to this vital medication which can help prevent relapse and improve quality of life. 🧡 Read more: nice.org.uk/news/articles/ne…
An image of red and white blood cells in the bloodstream. On top of the image is an orange block with white text which reads, ‘Blinatumomab approved for wider use in B-cell acute lymphoblastic leukaemia (B-ALL)’.

ALT An image of red and white blood cells in the bloodstream. On top of the image is an orange block with white text which reads, ‘Blinatumomab approved for wider use in B-cell acute lymphoblastic leukaemia (B-ALL)’.

1
6
13
578
The countdown is on – #Mycology2025 is 1 month away!⏰ 📅14th-15th of March 2025 | 📍QEII Centre, London 🔎Explore cutting-edge mycology 🤝Network with global experts 🎨Join FungART & showcase creativity Watch below & see why you should attend🔗ow.ly/yolI50UPnxC
2
6
487
Varun Mehra retweeted
Benlazar S M A@smbenlazar28 Jan 2025
Acute myeloid leukemia management and research in 2025 - Kantarjian - 2025 - CA: A Cancer Journal for Clinicians - Wiley Online Library acsjournals.onlinelibrary.wi…

Acute myeloid leukemia management and research in 2025

The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem...

acsjournals.onlinelibrary.wiley.com
26
82
3,644
Interesting data from @KingsCollegeNHS looking at autologous Treg cells in #AA - persistent st 6 months with responses in some patients. #ASH24 @ASH_hematology
2
9
368
Load more